veryone should have the opportunity to lead a healthy life. This requires that we advance equitable access to healthcare and address some of the world’s most devastating and neglected diseases.
That’s why Johnson & Johnson has long taken action to advance equitable access to our lifesaving medicines and health technologies and focuses on addressing diseases that disproportionately impact people in lower- and middle-income countries. These efforts resulted in our rise to second place in the 2022 Access to Medicine Index (ATMI), marking the sixth consecutive time Johnson & Johnson has featured among the top three performers in the Index and validating our decades-long, deliberate and focused access strategy.
Our colleagues and partners around the world work together every day to enable access to our innovative medicines and technologies in almost 100 lower- and middle-income countries. We apply access & pricing principles across our entire pharmaceutical portfolio, planning for access early in the research phase, while our dedicated global public health team applies a lab-to-last-mile approach to fight diseases like tuberculosis, HIV, Ebola, and intestinal worms: innovating across all that we do to develop and deliver much-needed medicines, strengthening health systems and supporting frontline health workers.
We recognize much more needs to be done and will continue working tirelessly, building on our approach to meet the needs of people today and the challenges the world faces tomorrow.
The impact of our efforts to advance access to medicines is reflected in Johnson & Johnson’s consistent high rank in the ATMI, which evaluates global companies’ access to medicine efforts. In 2022, we rose to second place, from third in 2021, marking the sixth consecutive time we’ve ranked among the top three companies worldwide, and underscoring the enduring nature of our commitment to people impacted by devastating and neglected diseases.
Through our access and pricing principles we are able to systematically plan for access across our entire portfolio, beginning at the early stages of discovery and development, ensuring that our medicines reach the people who need them most.
Our unique, industry-first Global Public Health unit exists to save lives and improve global health by working from the lab to the last mile of healthcare delivery to address the world’s most devastating and neglected diseases, which disproportionately impact much of the world.
From addressing endemic diseases like tuberculosis to emerging health threats like Ebola and dengue, we design innovative medicines and technologies that are fit for purpose for every community.
Our consistent track record validates our long-standing, focused strategy and is a testament to the work of our colleagues and partners around the world who work every day to meet the needs of patients in almost 100 LMICs.